Breaking Finance News

AbbVie Inc (NYSE:ABBV) target price raised to $74.86, issued a report today by Vetr Inc.

AbbVie Inc (NYSE:ABBV) had its target price raised to $74.86 by Vetr Inc. in a report released 07/06/2017. The new target price indicates a possible upside of 0.04% based on the company's last stock close price.

Yesterday AbbVie Inc (NYSE:ABBV) traded 0.27% higher at $71.97. The company’s 50-day moving average is $72.05 and its 200-day moving average is $66.76. The last stock close price is up 5.79% from the 200-day moving average, compared to the S&P 500 which has increased 0.05% over the same time. 3,248,300 shares of the stock were exchanged, down from an average trading volume of 5,519,340

See Chart Below

AbbVie Inc (NYSE:ABBV)

AbbVie Inc has a price-earnings ratio of 13.43 with a one year low of $55.06 and a one year high of $75.04 ABBV’s total market value is presently $0.

A total of 18 equity analysts have released a ratings update on ABBV. Four analysts rating the company a strong buy, ten analysts rating the company a buy, five analysts rating the company a hold, one analyst rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $70.22.

General Company Details For AbbVie Inc (NYSE:ABBV)

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.